INTRODUCTION
DNA vaccination using plasmid DNA (pDNA) is a method that was initially performed in mice by intramuscular injection 1 and was subsequently used with success in both infectious and malignant disease models. 2 Gene gun immunization by delivery of DNAcoated gold particles to the skin was reported to be more efficient in generating antigen-specific T cell and antibody responses in mice, although a TH2-bias of the emerging immune response was also observed. 3 The higher efficiency of gene gun DNA delivery to the skin compared with i.m. application is most likely to be explained by the high density of antigen-presenting cells (APC) such as dendritic cells (DC) in epidermal sites. Gene gun particle bombardment causes local injury ( ¼ inflammation/danger signal) and results in direct transfection of DC and non-immune cells such as keratinocytes. The latter may also express and secrete the antigen into the environment where it is taken up by DC (crosspriming). This process results in efficient T-cell priming within secondary lymphatic tissues. [4] [5] [6] [7] Although DNA vaccines have been very successful in inducing antigen-specific immune responses in mice, [8] [9] [10] immunogenicity in humans and large animals has so far been largely disappointing. 3, 9, 11 The reasons are diverse, but are mostly related to topics such as dosing, application route, tissue distribution and differences in toll-like receptor (TLR) expression patterns between mice and humans. 12 New experimental approaches aimed at amplifying the immune responses induced by DNA vaccines are therefore warranted. Several approaches have been pursued to improve the immunogenicity of DNA vaccines including the coexpression of immunomodulatory molecules such as cytokines and chemokines. 10, [13] [14] [15] [16] Chemokines such as CCR7-ligands Ebstein-Barr-Virus-inducedmolecule-1-ligand-chemokine (ELC/CCL19) and secondary lymphoid-tissue chemokine (SLC/CCL21) are key regulators of innate and adaptive immune responses, since they orchestrate migration of DC and T cells into secondary lymphatic tissues, thereby organizing immune synapse formation. [17] [18] [19] [20] CCL19 is constitutively expressed by cells distributed throughout the T-cell zones of lymph nodes, spleen and Peyer's patches. Additionally, recent studies suggest that DC themselves are able to secrete CCL19 during activation and migration. 21 Whereas immature steady-state DC residing in the tissues do not express the cognate CCL19 receptor, CCR7 is induced upon activation of DC, that is, by external infectious stimuli via TLR. 17 Upregulation of CCR7 that possibly coincides with autocrine CCL19 (and CCL21) production, leads to migration of activated mature DC into regional lymph nodes following a CCL19/CCL21 gradient. Since CCR7 is not only expressed by mature DC, but also by particular subsets of T-and B cells such as naive T cells, central memory T cells and activated B cells, CCR7-ligands increase the chance of interaction between DC, T-and B cells in secondary lymphatic tissue and thus regulate primary (or secondary) adaptive immune responses.
We have previously shown in a Her2/neu mouse tumor model that CCL19 is able to amplify both a TH1-polarized antigen-specific immune response and tumor protection by an intramuscular DNA vaccine. 22 We chose a prophylactic tumor vaccination model since therapeutic vaccination has been largely disappointing during the past decades, whereas vaccines able to induce protective immunity in the situation of minimal residual disease are possibly more appropriate for clinical application. 23 In this study, we asked (1) whether the adjuvant activity of CCL19 can also be observed after intradermal gene gun delivery of DNA, (2) which application route (intramuscular or intradermal) should be preferred for the further preclinical development of a Her2/neu-CCL19 DNA vaccine and (3) which role can be attributed to B cells (which may also express CCR7) in our system.
MATERIALS AND METHODS

Cell lines
The mouse mammary tumor cell line D2F2 is derived from a spontaneous mammary tumor that arose in a Balb/c background from the hyperplastic alveolar nodule cell line D2. D2F2/E2 is transfected with the human Her-2/ neu expression vector pCMV/E2 and the selectable pDNA pRSV/neo. The Her2/neu-expressing cell line D2F2/E2 was maintained in Dulbecco's Modified Eagle's Medium (Biochrom, Berlin, Germany) containing 800 mg ml À 1 of G418 (Life Technologies, Karlsruhe, Germany). These cell lines were kindly provided by Dr Thomas Kammertö ns (MDC, Berlin, Germany). The human Her2/neu-overexpressing breast cancer cell line SK-BR3 was purchased from the American Type Culture Collection cell bank (ATCC, Wesel, Germany) and used for flowcytometric detection of Her2/ neu antibodies in the serum of the animals. The cell line was maintained in RPMI medium (Lonza, Cologne, Germany) supplemented with 10% FCS (fetal calf serum) (Biochrom), 2.5 mM 2-mercaptoethanol (Invitrogen, Darmstadt, Germany), 0.5 mM sodium pyruvate (Lonza), 2 mM L-glutamate (Lonza), 0.1 mM minimum essential medium non-essential amino acids (Lonza) and 100 U ml À 1 penicillin/streptomycin (Lonza) ( ¼ complete medium, CM). The expression of Her-2/neu protein in SK-BR3 cells was confirmed by fluorescence-activated cell sorting staining using phycoerythrin-conjugated anti-human Her-2/neu antibody (BD Pharmingen, Heidelberg, Germany). The percentage of Her2/neu expression in the D2F2/E2 cells used in our experiments always exceeded 95%.
Plasmids pVax was purchased from Invitrogen. pDNA (Her-2/neu) encoding human Her-2/neu was kindly provided by Dr S Preise and Dr T Kammertö ns (MDC). The Her2/neu plasmid vector pVax/E2A contains the E2A gene from pCMV/ E2A, which was cloned into the expression vector pVax. E2A contains mutations at nucleotide positions 2257-2258 that result in a lysine to alanine exchange at position 753 of the amino-acid sequence. This alteration leads to elimination of tyrosine signaling in the Her2/neu protooncogene, which is an important safety feature for potential clinical vaccine development. The plasmid pDNA(CCL19) consists of pcDNA3 encoding human CCL19 under the control of a CMV promoter. The plasmids were amplified in Escherichia coli X1-blue strain (Agilent Technologies, Amsterdam, The Netherlands) and purified using the EndoFree Giga-Prep-Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions.
Animals
Female 6-to 8-week-old Balb/c mice (H-2k d ) mice purchased from Charles River (Sulzfeld, Germany) and B-cell-deficient mMT (H-2k d ) mice with a Balb/c genetic background, kindly provided by Dr T Kammertö ns (MDC) were housed in our animal facility under standard pathogen-free conditions. Experiments have been approved by local authorities (LAGeSo, Berlin) and performed according to the German animal protection law.
Immunization and tumor challenge protocol
Mice were injected twice on days 1 and 15, either by DNA-coated gold particle bombardment onto the shaved abdomen using a Helios gene delivery system (Bio-Rad, Munich, Germany) or by i.m injection using syringe and needle. For gene gun vaccination, DNAs were coated onto 0.8-1.5 mm gold particles following a protocol developed for the helium-driven gene delivery systems from Bio-Rad. In all, 2 mg DNA per immunization were delivered in two shots with a helium discharge pressure of 300-400 psi. Intramuscular immunizations were performed with 100 mg plasmid in a volume of 100 ml PBS. Each experimental group consisted of 5-10 mice. Mice were injected with pDNA(Her2/neu) plus pDNA(CCL19), pDNA(Her2/neu), pDNA(CCL19) or mock vector alone. As further negative controls, PBS was used for intramuscular vaccination and uncoated gold particles for gene gun immunization. In all, 10 days later each vaccinated mouse was challenged with 2 Â 10 5 D2F2/E2 tumor cells. The appearance and growth of tumors in the mice were then monitored 1-2 times per week. Progressively growing masses over 1 mm in diameter were regarded as tumors and tumor volumes were calculated as 1/6p
Preparation of splenocytes
Spleens were aseptically removed and a single-cell suspension was generated in CM. Erythrocytes were lysed using erythrocyte lysis buffer (EDTA þ NH 4 CL þ Na 2 CO 3 ). Finally, splenocytes were washed twice in RPMI-1640 and subsequently used for immunological assays.
ELISpot Assays
For ELISpot assays, splenocytes were seeded into 3-4 wells (2 Â 10 5 splenocytes per well) of a g-interferon (g-IFN)-or interleukin-4 (IL-4)-ELISpot plate (ELISpot kit, Pharmingen, Heidelberg, Germany). Peptides were added at a concentration of 1 mg ml À 1 . Plates were incubated overnight, developed according to the manufacturer's instructions and analyzed using an ImmunoSpot reader system (CTL Europe, Bonn, Germany). Peptide-specific responses were defined as having (1) a ratio of specific peptide:control X2 and (2) an absolute number of spots420. Results were expressed as 'spots per 10 6 splenocytes'. The following Her2/ neu peptides were used: (1) Kd restriction and potential immunogenicity in mice has previously been shown for most of these peptides. 24 Using the BIMAS epitope prediction algorithm (www.bimas.nih.gov), most peptides are high affinity binders for K d . Only peptides 1c, 2a and 2c are predicted to have a low affinity for Kd. All peptides were purchased from Wita GmbH (Berlin, Germany) and had a purity of 495%.
Pentamer staining
To detect anti-p63 Her2/neu-specific CD8 þ T cells in peripheral blood, lymphocytes isolated from the blood of mice on day 6 or from spleens on day 7 after the second vaccination were stained with a phycoerythrinlabeled pentamer that recognizes the epitope Her2/neu-p63 (ProImmune Ltd., The Magdalen Centre, Oxford, UK) using the manufacturer's protocol. Lymphocytes were then further stained with a mix of antibodies containing CD3-FITC, CD8-APC (Pharmingen) and CD19 PerCP-Cy5.5 (Biolegend, Fell, Germany). Stained cells were detected using a BD FACSCanto and analysis was performed with the FlowJo software (Ashland, OR, USA).
Detection of anti-Her2/neu antibodies
Detection of antigen-specific antibodies in the serum by means of flow cytometry offers the advantage that it can be performed even if the respective recombinant protein is not easily available or if its production is very cost-intensive. The assay uses target cells that express the cognate antigen to bind serum antibodies that are detected in a second step by flow cytometry using labeled anti-Ig antibodies. 25 
Statistical methods
Analysis of variance of the means of three or more groups was performed using the PRISM software (GraphPad Software, La Jolla, CA, USA). The Student's t-test was used to compare the means of two groups. Results are representative for two independent experiments. A P-value of o0.05 was considered significant. RESULTS CCL19 enhances tumor protection by the Her2/neu DNA vaccine both after intradermal gene gun and intramuscular immunization: gene gun is superior to intramuscular vaccination The activity of CCL19 as an adjuvant for intradermal gene gun Her2/neu DNA vaccination was evaluated in a Balb/c mouse tumor model with syngeneic Her2/neu þ tumors. Animals were immunized twice i.d. by gene gun or i.m. on days 1 and 15, tumor challenge with D2E2/F2 tumor cells was performed on day 25. DNA vaccination was performed with pDNA(Her2/neu) or pDNA(Her2/neu) plus pDNA(CCL19). Control groups were vaccinated with pDNA(CCL19), mock vector (pVax) or gold particles/PBS alone (Figures 1a and b) . On day 60 after tumor challenge, the percentage of tumor-free gene gun-immunized mice was 90% with pDNA (Her2/neu) plus pDNA (CCL19), 60% with pDNA (Her2/ neu), 10% with pDNA (CCL19) and 0% with mock vector or gold particles alone, clearly showing that CCL19 is able to enhance the efficacy of the Her2/neu DNA vaccine after intradermal gene gun immunization (Figure 1b) . Improvement of tumor protection by CCL19 was maintained until day 250 after tumor challenge (70 vs 40% tumor-free mice; Figure 1b) , showing that the pDNA(Her2/ neu) plus pDNA(CCL19) DNA vaccine was able to convey longterm protection from tumor growth. Tumor protection of the pDNA(Her2/neu) plus pDNA(CCL19) DNA vaccine was more efficient when the vaccine was administered intradermally by gene gun as compared with intramuscular application: Short-term tumor protection until day 60 after tumor challenge was 90% after gene gun immunization as compared with 32% after i.m. vaccination (Figures 1a and b) . The advantage of gene gun immunization over i.m. immunization was maintained until day 250 after tumor challenge (70 vs 30% tumor-free animals; Figures  1a and b) . Interestingly, vaccination efficacy with pDNA(Her2/neu) alone was higher after gene gun immunization as compared with i.m. vaccination: after gene gun immunization, 60% of the mice remained tumor-free until day 60 and 40% were still tumor-free on day 250. In contrast, all mice immunized i.m. had developed tumors by day 60 (Figures 1a and b) . In control animals that had been immunized with pDNA(CCL19), pVax or gold particles/PBS, no relevant tumor protection could be observed (Figures 1a and b) .
T-cell immune responses after gene gun and intramuscular immunization: influence of CCL19 as an adjuvant Anti-Her2/neu T-cell responses were assessed in each group of animals 6-8 days after the second vaccination by g-IFN-and IL-4 ELISpot assays and pentamer staining both after gene gun and i.m. immunization as described above. Intramuscular vaccination with pDNA(Her2/neu) alone was not able to induce significant anti-Her2/neu immune responses (Figure 2a) , whereas very strong Her2/neu-specific T-cell responses were detected by g-IFN ELISpot after intradermal gene gun immunization (Figure 2b ).
The anti-Her2/neu T-cell responses in our experimental system were mainly directed against the extracellular domain of Her2/ neu. This has previously been described for i.m. immunization 22, 26 and was now confirmed for intradermal vaccination (Figure 2b ). Interestingly, CCL19 was able to amplify anti-Her2/neu T-cell responses after intramuscular immunization (Figure 2a) , whereas this was not the case after gene gun immunization (Figure 2b) . On the contrary, after gene gun vaccination T-cell responses with pDNA(Her2/neu) plus pDNA(CCL19) were lower than after immunization with pDNA(Her2/neu) alone despite better tumor protection with the vaccine containing CCL19-encoding DNA (Figures 1a and 2b) . IL-4 ELISpot did not show any Her2/neuspecific responses, neither after gene gun immunization nor after i.m. vaccination (data not shown). In the control groups that had received pDNA(CCL19), pVax or gold particles/PBS, no significant T-cell responses were detected (Figures 2a and b) . The data obtained by g-IFN-ELISpot assays were strongly supported by a structural T-cell assay using pentamers that were able to detect Her2/neu-p63-specific T cells: the intramuscular vaccine was not able to induce p63-specific T cells, whereas intradermal gene gun 5 Her2/neu þ syngeneic D2F2/E2 tumor cells. Tumor growth was then monitored until day 250. Coexpression of CCL19 was able to improve tumor protection of the immunized animals. n ¼ 10 for each group of mice. *Statistically significant vs pDNA(Her2/neu) (Po0.01). **Statistically significant vs all control groups (Po0.01).
CCL19 improves Her2/neu DNA vaccination by gene gun T Nguyen-Hoai et al immunization elicited a strong p63-specific CD8 þ T-cell response ( Figure 3 ). Pentamer staining not only confirmed the superior T-cell responses after gene gun immunization, it also showed that the level of p63-specific T cells was highest after vaccination with pDNA(Her2/neu) alone as compared with pDNA(Her2/neu) plus pDNA(CCL19), thereby confirming the results obtained by g-IFN-ELISpot assay (Figures 2b and 3 ).
Humoral anti-Her2/neu immune responses after intradermal gene gun and intramuscular immunization Humoral anti-Her2/neu immune responses after vaccination with gene gun or after intramuscular immunization were studied 7 days after the second vaccination by flowcytometric quantification of Her2/neu-specific antibodies in the sera of the animals. Intramuscular immunization with pDNA(Her2/neu) or pDNA (Her2/neu) plus pDNA(CCL19) did not induce significant humoral immune responses (data not shown). In contrast, gene gun immunization with pDNA(Her2/neu) led to significant anti-Her2/ neu antibody levels although additional application of pDNA(CCL19) was not able to further amplify this response (Figure 4 ). CCL19 as an adjuvant for DNA vaccination in B-cell-deficient mice (mMT) Tumor protection after vaccination by gene gun or intramuscular application. In order to further elucidate the mechanism by which CCL19 enhances tumor protection by the Her2/neu DNA vaccine, tumor challenge experiments and analysis of the antiHer2/neu T-cell responses were investigated in mMT mice which are B-cell-deficient and have a Balb/c genetic background. Mice were immunized i.d. or i.m. with pDNA(Her2/neu) or pDNA(Her2/ neu) plus pDNA(CCL19), respectively. Control groups were vaccinated with pDNA(CCL19), mock vector (pVax) or gold particles/PBS alone (Figures 5a-c) . Again, intradermal application of the vaccine by gene gun was compared with intramuscular injection using the same experimental setting as in wild-type (WT) mice. After intramuscular immunization with pDNA(Her2/neu), 30% of the mice remained tumor-free until day 60 (Figure 5a ). Vaccination with pDNA(Her2/neu) plus pDNA(CCL19) led to a slight initial improvement in tumor protection; however, the difference between groups of mice immunized with pDNA(Her2/ neu) alone or pDNA(Her2/neu) plus pDNA(CCL19) waned by day 56 (Figure 5a ). Tumor protection in mMT mice after gene gun immunization again showed better tumor protection as compared with intramuscular vaccination (72 vs 30% tumor-free mice on day 60 after vaccination with pDNA(Her2/neu) (Figures 5b and c) . However, comparing the results observed in WT mice with mMT mice the following observations could be made:
(1) The level of tumor protection after gene gun vaccination with pDNA(Her2/neu) alone in mMT mice was slightly higher in the short term (72 vs 60% on day 60) but lower in the long term (28 vs Anti-Her2/neu T-cell responses in mMT mice after intradermal and intramuscular immunization. Anti-Her2/neu T-cell responses were assessed 6-7 days after the second vaccination by g-IFN-/IL-4-ELISpot assays and by pentamer staining as described above. Intramuscular vaccination with pDNA(Her2/neu) alone was not able to induce a significant anti-Her2/neu T-cell response, comparable with the results seen in WT mice (data not shown). An additional application of pDNA(CCL19) was able to enhance T-cell responsiveness of the pDNA(Her2/neu) vaccine at a low level, although a Her2/neu-specific response could not be detected (data not shown). After intradermal immunization by gene gun, pDNA(Her2/neu) alone elicited a vigorous anti-Her2/ neu g-IFN T-cell response comparable to that seen in WT mice. T-cell responses were again directed against peptides corresponding to the extracellular domain of Her2/neu ( Figure 6 ). However, in contrast to the results obtained in WT mice, additional application of pDNA(CCL19) led to an improvement of anti-Her2/neu T-cell immunity in mMT mice (Figure 6a ). These results were again confirmed by pentamer staining of Her2/neu-p63-specific T cells (Figure 6b ).
DISCUSSION
Our study shows that Her2/neu DNA vaccination by intradermal gene gun delivery achieves better tumor protection than intramuscular injection and that CCL19 is a potent adjuvant for both intramuscular and intradermal immunization. The preclinical Her2/neu mouse tumor model used in the current study is well established and has previously been applied in other investigations. [27] [28] [29] It is particularly appropriate for the initial evaluation of adjuvants for genetic immunization and successful candidate molecules may subsequently be evaluated in transgenic mouse models, which are more suitable with regard to the preexisting tolerance towards tumor antigens observed in patients. 30 Intramuscular application of pDNA(Her2/neu) alone was not able to induce protection from a subsequent tumor challenge, whereas intradermal delivery of the same vaccine by gene gun led to longterm protection in 40% of the animals. Our data suggest that this improvement in tumor protection after gene gun delivery was mediated by Her2/neu-directed T cells and a humoral anti-Her2/ neu immune response. (Figures 2 and 4) . In contrast, Her2/neuspecific antibodies were not detectable over background levels after intramuscular immunization. This difference between intramuscular and intradermal DNA delivery by gene gun is very likely to be caused by different patterns of 'target cells' at the vaccination site. In both cases, direct and indirect transfection of bone marrow-derived APC may play a major role in the induction of immunity. 8, 31 It is generally believed that DNA-coated gold particles target APC in the upper layer of the skin where they exist at a very high density. 4, 5, [32] [33] [34] [35] Furthermore, local injury by gene gun particle bombardment may induce a local inflammatory environment supporting DC maturation and subsequent T-cell activation. 4, 5, [36] [37] [38] Unexpectedly, after gene gun application, Her2/ neu peptide-specific CD8 þ g-IFN T-cell responses were lower after coadministration of CCL19, despite better tumor protection compared with Her2/neu alone. Humoral anti-Her2/neu immune responses as measured by total anti-Her2/neu IgG were comparable between both groups of mice (Figure 4) , suggesting that CCL19 did not increase the Her2/neu-specific humoral immune response. Since CCL19 is a chemokine with pleiotropic effects involving effector cell populations that belong to both the innate and the adaptive immune system (T cells, B cells, DC, NK cells, neutrophils), 17, 39, 40 the in vivo mechanism of action of CCL19 is complex and therefore difficult to delineate. Since CCR7, the cognate CCL19 receptor is also expressed on (activated) B cells, we decided to evaluate vaccine efficacy in B-cell-deficient mMT mice. In these B-cell-deficient mMT mice, tumor protection by the gene gun-delivered Her2/neu DNA vaccine is maintained. However, most strikingly, the adjuvant activity of CCL19 in terms of improved tumor protection was abolished after both intradermal and intramuscular application. Surprisingly and in contrast to WT mice, an amplification of the CD8 þ T-cell response was observed in these mMT mice vaccinated with Her2/neu plus CCL19 by gene gun although this was not paralleled by an improved tumor protection.
Obviously, the level of Her2/neu-specific g-IFN T-cell responses measured ex vivo does not necessarily reflect the extent of tumor protection observed in vivo. This discrepancy between T-cell assays and tumor response has been described in many studies, particularly in vaccination trials in cancer patients. 41 In our experimental setting, there are several possible explanations: (1) CD8 þ T cells are not the most important effector cells for tumor rejection after gene gun immunization with Her2/neu plus CCL19 in WT mice. The latter point is indeed supported by a strong antiHer2/neu antibody response after gene gun immunization (but not after i.m. vaccination) and by depletion experiments in the same tumor model as well as in B16 melanoma showing that CD4 þ T cells play a pivotal role for tumor protection 27, 42, 43 Furthermore, it has previously been demonstrated in a Her2/neu þ tumor model, that multiple antigen-specific and non-specific immune mechanisms are responsible for tumor rejection, 44 (2) splenic T cells (which were used in our assays) do not sufficiently reflect systemic responses or responses at the tumor site and (3) T-cell assays used did not include the most relevant tumor rejection epitopes. Although our data show that Her2/neu vaccines are still immunogenic in B-cell-deficient mice, they also show that B cells are involved at least in mediating the adjuvant activity of CCL19. It seems very unlikely that this is simply due to different levels of antibody-mediated immunity since CCL19 does not alter total anti-Her2/neu IgG levels in immunized animals ( Figure 4) . Our results suggest a direct role for B cells as APC in the emerging anti-Her2/neu immune response. An important role for B cells as APC has previously been described particularly for gene gun vaccination. [45] [46] [47] [48] [49] Several studies suggest that B cells, in particular after antigen-uptake via surface receptors may express antigen-presenting features that hitherto were only attributed to DC. 50 Particularly in situations with a low antigen load (as might be the case after i.d. delivery of very low amounts of DNA), antigen-specific B cells may enrich antigen via their (antigenspecific) surface receptors and subsequently present antigen to T cells (predominantly CD4 þ T cells) in lymphatic tissues. 46, 47, 51, 52 Assuming that in fact antigen-presenting B cells play an important role for the adjuvant activity of CCL19 in the mouse model used in our study, it still remains an open question as to why CCL19 leads to an amplification of CD8 þ T-cell responses in mMT mice, but not in WT mice. Nevertheless, it has been previously concluded from experimental mouse models 53, 54 that B cells are crucial for the development of TH2 responses by triggering IL-4 production in T cells or that they may even suppress tumor immunity, 55 possibly by competition with other APC as has previously been suggested by Qin et al. 56 Since Her2/neu-directed immune responses after gene gun immunization are mediated by T cells, antibodies and many other immune mechanisms, 44 Her2/neu-specific T cells in B-cell-deficient mice (which contain higher numbers of T cells than WT mice, data not shown) might partially compensate for the lack of anti-Her2/neu antibodies, thereby re-establishing a direct correlation between tumor protection and ex vivo T-cell responses. For the first time, our study provides evidence that antigen-presenting B cells may play an important role in CCL19-mediated tumor protection. We suggest that clinical evaluation of Her2/neu DNA vaccines would be most appropriate in Her2/neupositive breast cancer in a clinical situation of minimal residual disease after successful systemic treatment or surgery.
